M&A deals, company strategies, pipeline updates and more
Follow our coverage of the 2019 J.P. Morgan Healthcare Conference in San Francisco
Terns names ex-Gilead executive as CMO; Spectrum sells all FDA-approved drugs to Aurobindo; Aslan's varlitinib fails in gastric cancer.
A Sun distributor allegedly inked transactions worth $816 million with a firm controlled by Sun’s co-promoter Sudhir Valia.
Spectrum is offloading seven drugs and transferring 40% of its total workforce to Aurobindo in a deal to "laser-focus" on novel cancer drugs.
Pfizer has formed a partnership to manufacture some of its drugs in the rapidly growing Asian market.
Pfizer is offering some 1,700 door-heading employees "an attractive financial scheme that is significantly higher than the legal requirements."
Concerned parents raised the specter of similar breaches dating back as early as 2010, as the government vows a thorough probe.
Pfizer closes two Hospira plants in India; Gilead licenses Yuhan's NASH programs; Fujifilm is expanding its footprint in the U.S.
Pfizer's plan to close two legacy Hospira plants in India puts 1,700 jobs stationed there at risk.
Takeda will probably not sell its OTC business to help pay off the $31 billion loan it’s taking to finance the Shire takeover, its CEO says.
Seeing an opportunity, Japan’s Fujifilm will build a U.S. stem cell manufacturing facility not only for its own efforts but also as a CDMO.